ReviewMycology2025
New bioactive secondary metabolites from fungi: 2024.
Review in Mycology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Discovery of new α-pyrone derivative with α-glucosidase inhibitory activity from the fungus Acremonium persicinum.The Journal of antibiotics · 2026Article
- Sulphopreussomerins: Sulfur-Containing Preussomerins Isolated from the Marine-Derived Fungus Pyrenochaetopsis indica.Journal of natural products · 2026Article
- Article
- Water Soluble-Nitrogenous Secondary Metabolites From Talaromyces annesophieae MD2 Exhibit Anti-Bacterial, Anti-Cancer, Anti-Oxidant, and Cytoprotective Activities.MicrobiologyOpen · 2026Article
- Culturable Fungi Recovered from Deep-Sea Sediments: Diversity, Phylogenetic Placement, and In Vitro Antagonistic Activity Against Phytopathogenic Fungi.Journal of fungi (Basel, Switzerland) · 2026Article
- An Exploratory LC-HRMS Metabolomics Study of Culture Medium-Dependent Metabolic Variation and Bioactivity in Ten Fungal Strains.International journal of molecular sciences · 2026Article
- From Pigment Chemistry to Nanomaterials: Fungal Pigments as Reducing and Stabilizing Agents in Green Nanoparticle Synthesis.Microorganisms · 2026Review
- Untargeted GC-MS metabolic profiling of Eurotium chevalieri AUMC 16390 (PX498623) reveals a putative steroidal metabolite with antibacterial and anti-inflammatory potential.BMC biotechnology · 2026Article
- Diversity of Microscopic Fungi.Journal of fungi (Basel, Switzerland) · 2026Article
- New indole diketopiperazine from the fungus Penicillium chrysogenum.The Journal of antibiotics · 2026Article
- New Pyridinone Alkaloid and Polyketide from theBiomolecules · 2026Article
- New Chlorinated Meroterpenoids with Antifungal Activity from the Deep-Sea-Derived FungusMarine drugs · 2026Article
- Mechanistic evidence and assumptions in mycotoxin-gut interaction.Frontiers in fungal biology · 2026Article
- Elucidating the mycochemistry and anticancer efficacy of F5 fraction of ethanolic extract of Daldinia eschscholtzii.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fungi have been recognised as a prolific source of structurally unique secondary metabolites with promising pharmacological properties. This review comprehensively summarises the chemical architectures, bioactivities, and research strategies for new fungal-derived natural products, focusing on representative studies published in 2024. A total of 907 novel fungal-derived compounds are systematically cataloged (isomers are also contained in the total count), including 284 polyketides, 362 terpenoids, 28 steroids, 108 alkaloids, 75 peptides, and 50 glycosides, while highlighting cutting-edge methodologies such as metabolomics-guided discovery platforms and biosynthetic pathway engineering. By establishing connections between chemical novelty and therapeutic value, this review not only provides strategic guidance for fungal chemical diversity exploration but also illuminates their transformative potential in overcoming drug discovery bottlenecks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.